Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

Dr. Hardeep Singh Tuli is an Assistant Professor at the Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala. He previously served as a Lecturer at the Department of Applied Sciences, Institute of Science and Technology, Klawad, Yamunanagar (2009-2011), India. His research interests are focused on the isolation, characterization and biochemical evaluation of natural metabolites as anticancer agents. He has served as a reviewer for several international journals, and as a guest editor for the journal Frontiers in Pharmacology. He has more than 9 years of teaching and research experience in pharmacology, mammalian physiology, and natural products. He has published more than 70 papers in peer-reviewed international journals and authored a number of book chapters. In addition, Dr. Tuli is editorial board member of various national and international scientific research journals.

• Chapter 1. History of oncotherapies in cancer biology.- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs.- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer.- Chapter 4.  Apoptotic cell death: important cellular process as chemotherapeutic target.- Chapter 5. Regulatory roles of autophagy in cancer.- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances.- Chapter 7. Inflammatory mediators: Potential drug targets in cancer.- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer.- Chapter 10. Metastasis: A major driver of cancer pathogenesis.- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.